Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Inv. presentation
Quarterly results

Atea Pharmaceuticals, Inc. (AVIR) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
11/15/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/02/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/21/2021 4 Murphy Polly A. (Director) has filed a Form 4 on Atea Pharmaceuticals, Inc.
Txns: Bought 12,000 shares @ $8.5663, valued at $102.8k
06/21/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2021 4 Lucidi Bruno (Director) has filed a Form 4 on Atea Pharmaceuticals, Inc.
Txns: Granted 34,025 options to buy @ $23.39, valued at $795.8k
06/21/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
06/21/2021 4 Murphy Polly A. (Director) has filed a Form 4 on Atea Pharmaceuticals, Inc.
Txns: Granted 34,025 options to buy @ $23.39, valued at $795.8k
05/20/2021 4 Adams Jerome M. (Director) has filed a Form 4 on Atea Pharmaceuticals, Inc.
Txns: Granted 56,670 options to buy @ $23.43, valued at $1.3M
02/01/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/01/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/01/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/01/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/01/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/01/2021 4 Foster Wayne (See Remarks) has filed a Form 4 on Atea Pharmaceuticals, Inc.
Txns: Granted 71,750 options to buy @ $73, valued at $5.2M
11/05/2020 4 Cormorant Asset Management, LP (Former 10% Owner) has filed a Form 4 on Atea Pharmaceuticals, Inc.
Txns: Converted 6,411,355 shares @ $0
Converted 1,000,000 convertible preferred @ $0
Converted 1,650,165 convertible preferred @ $0
Converted 2,631,580 convertible preferred @ $0
Converted 712,250 convertible preferred @ $0
Converted 417,360 convertible preferred @ $0
11/04/2020 4 Rock Springs Capital Management LP (10% Owner) has filed a Form 4 on Atea Pharmaceuticals, Inc.
Txns: Converted 1,412,016 shares @ $0
Converted 282,403 shares @ $0
Bought 242,708 shares @ $24, valued at $5.8M
Bought 7,292 shares @ $24, valued at $175k
Converted 890,313 convertible preferred @ $0
Converted 521,703 convertible preferred @ $0
Converted 178,063 convertible preferred @ $0
Converted 104,340 convertible preferred @ $0
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy